Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SB 883Session 89R

What changed between versions

7 paragraphs changed+2 words added−49 removed

Highlighted text was added in the newer version. Struck-through text was removed.

By: Paxton, Hall,et Sparksal.

S.B. No. 883

(In the Senate - Filed January 23, 2025; February 13, 2025,

read first time and referred to Committee on Health & Human

Services; April 7, 2025, reported favorably by the following vote:

Yeas 8, Nays 1; April 7, 2025, sent to printer.)

Click here to see the committee vote

A BILL TO BE ENTITLED

56 unchanged paragraphs

AN ACT

relating to patient access to prescription drugs for off-label use

for COVID-19 treatment.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. (a) This Act shall be known as the Right to Treat

Act.

(b) The legislature finds that:

(1) the relationship between a physician and patient

is valued;

(2) during the COVID-19 pandemic, many patients have

been frustrated to learn that their physicians are discouraged from

prescribing for off-label use prescription drugs that may aid in

the patient's treatment of and recovery from COVID-19; and

(3) this Act is intended to enable a patient to access

and a physician to prescribe for off-label use prescription drugs

that may aid in the patient's treatment of and recovery from

COVID-19.

SECTION 2. Subtitle C, Title 6, Health and Safety Code, is

amended by adding Chapter 491 to read as follows:

CHAPTER 491. OFF-LABEL USE OF PRESCRIPTION DRUGS FOR COVID-19

TREATMENT

Sec. 491.001. DEFINITIONS. In this chapter:

(1) "COVID-19" means the 2019 novel coronavirus

disease.

(2) "Off-label use" means the use of a prescription

drug approved for use by the United States Food and Drug

Administration in a manner other than the approved use.

(3) "Physician" means an individual licensed to

practice medicine in this state.

Sec. 491.002. APPLICABILITY. This chapter applies only to

the prescribing of a prescription drug the United States Food and

Drug Administration has approved for human use.

Sec. 491.003. PROHIBITED STATE INTERFERENCE WITH PATIENT

ACCESS TO OFF-LABEL USE OF PRESCRIPTION DRUG. An official,

employee, or agent of this state may not prohibit or restrict a

physician from prescribing for off-label use a prescription drug to

treat a patient who is exposed to or diagnosed with COVID-19.

Sec. 491.004. NO CAUSE OF ACTION CREATED. This chapter does

not create a private or state cause of action against a manufacturer

of a prescription drug approved by the United States Food and Drug

Administration or against a physician or any other person involved

in the care of a patient who is exposed to or diagnosed with

COVID-19 for any harm to the patient resulting from the off-label

use of the drug in the treatment of COVID-19.

Sec. 491.005. PROHIBITED ACTION AGAINST PHYSICIAN'S

LICENSE. Notwithstanding any other law, the Texas Medical Board

may not revoke, fail to renew, suspend, or take any other adverse

action against a physician's license under Subchapter B, Chapter

164, Occupations Code, based solely on the physician's prescribing

a prescription drug for off-label use to treat a patient who is

exposed to or diagnosed with COVID-19, provided the physician's

treatment of the patient meets the medical standard of care.

SECTION 3. This Act takes effect immediately if it receives

a vote of two-thirds of all the members elected to each house, as

provided by Section 39, Article III, Texas Constitution. If this

Act does not receive the vote necessary for immediate effect, this

Act takes effect September 1, 2025.

* * * * *

Back to the full text